Methods of Treating Inflammatory Pain

1 . A method for preventing and/or treating inflammatory pain and/or symptoms of inflammatory pain, comprising peripheral administration to the individual of an effective amount of an anti-CGRP antagonist antibody.

2 . The method according to claim 1 , wherein the medicament is prepared to be peripherally administered.

3 . The method according to claim 1 , wherein the medicament is administered peripherally.

4 . The method according to claim 1 , wherein the medicament is prepared to be administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, locally and/or intramuscularly.

5 . The method according to claim 4 , wherein the medicament is prepared to be administered subcutaneously or intravenously.

6 . The method according to claim 1 , wherein the anti-CGRP antagonist antibody acts peripherally on administration.

7 . The method according to claim 1 , wherein the inflammatory pain is arthritic pain.

8 . The method according to claim 7 , wherein the arthritic pain is osteoarthritis pain.

9 . The method according to claim 1 , wherein the anti-CGRP antagonist antibody:

(a) binds to CGRP;

(b) blocks CGRP from binding to its receptor;

(c) blocks or decreases CGRP receptor activation;

(d) inhibits blocks, suppresses or reduces CGRP biological activity;

(e) increases clearance of CGRP; and/or

(g) inhibits CGRP synthesis, production or release.

10 . The method according to claim 1 , wherein the anti-CGRP antagonist antibody:

(i) is a human antibody,

(ii) is a humanized antibody,

(iii) is a monoclonal antibody,

(iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasmon resonance at 37° C.); and/or

(v) has a half life in-vivo of at least 7 days.

11 . The method according to claim 1 , wherein the anti-CGRP antagonist antibody specifically binds to the C-terminal region of CGRP.

12 . The method according to claim 10 , wherein the anti-CGRP antagonist antibody specifically recognises the epitope defined by the sequence GSKAF.

13 . The method according to claim 1 , wherein the anti-CGRP antibody comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 or 19.

14 . The method according to claim 1 , wherein the anti-CGRP antibody comprises a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2 or 20.

15 . The method according to claim 14 , wherein the anti-CGRP antibody further comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 or 19.

16 . The method according to claim 1 , wherein the anti-CGRP antibody comprises at least one CDR selected from the group consisting of:

(a) CDR H1 as set forth in SEQ ID NO: 3 or 21;

(b) CDR H2 as set forth in SEQ ID NO: 4 or 22;

(c) CDR H3 as set forth in SEQ ID NO: 5 or 23;

(d) CDR L1 as set forth in SEQ ID NO: 6 or 24;

(e) CDR L2 as set forth in SEQ ID NO: 7 or 25;

(f) CDR L3 as set forth in SEQ ID NO: 8 or 26; and

(g) variants of L1, L2 and H2.

17 . The method according to claim 1 , wherein the anti-CGRP antibody comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 and a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2.

18 . The method according to claim 1 , wherein the anti-CGRP antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867.

19 . The method according to claim 1 , wherein the anti-CGRP antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866.

20 . The method according to claim 1 , wherein the anti-CGRP antibody is produced by the expression vectors with ATCC Accession Nos. PTA-6867 and PTA-6866.

21 .- 31 . (canceled)